Guest:
John LaMattina, Senior Partner, Pure Tech Ventures Bio and Contact Info
Listen (6:27) Comparing drug approvals: 2014 with 1996
Listen (7:10) More rational drug development?
Listen (1:58) Did public image of big pharma improve last year?
Listen (7:00) The Peter Bach argument
Listen (5:16) Who is winning the debate?
John LaMattina, the former president of Pfizer Global Research, is spending his semi-retirement cultivating the brand of public defender of pharma. As a contributor to Forbes, he showcases some of the great stories of drug development and offers counter punches to pharma’s detractors.
His recent column: FDA Approvals 1996 vs. 2014: The Two Most Prolific Years, But Stark Differences provides the context for today’s interview.
After a look at what is now seen as a banner year for drug development, LaMattina comments on highlights from last week’s JP Morgan Healthcare Conference in San Francisco. He's excited not only about all the business deals, but the new science as well.
The interview ends with a discussion about the debate over drug pricing, and who John thinks is winning it.
